Compare Stocks: HRMY, LQDA, LNTH, and BLTE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$157.23 0.0%	$148.62	$60.00 ▼ $200.00	$6.30B	-1.22	193,225 shs	59,530 shs
HRMY Harmony Biosciences	$37.99 -2.0%	$34.76	$25.52 ▼ $40.87	$2.19B	0.96	861,335 shs	849,860 shs
LNTH Lantheus	$101.47 +0.4%	$103.98	$47.25 ▼ $111.86	$6.60B	-0.03	1.03 million shs	1.25 million shs
LQDA Liquidia	$89.16 +0.9%	$74.79	$19.02 ▼ $91.36	$7.91B	0.58	1.78 million shs	516,902 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	+1.60%	+0.85%	+7.26%	+0.68%	+125.35%
HRMY Harmony Biosciences	+8.93%	+8.41%	+4.08%	+18.30%	+9.12%
LNTH Lantheus	-0.08%	-1.49%	-7.99%	+17.37%	+41.49%
LQDA Liquidia	+5.40%	+1.80%	+11.97%	+109.73%	+353.70%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$157.23 0.0%	$148.62	$60.00 ▼ $200.00	$6.30B	-1.22	193,225 shs	59,530 shs
HRMY Harmony Biosciences	$37.99 -2.0%	$34.76	$25.52 ▼ $40.87	$2.19B	0.96	861,335 shs	849,860 shs
LNTH Lantheus	$101.47 +0.4%	$103.98	$47.25 ▼ $111.86	$6.60B	-0.03	1.03 million shs	1.25 million shs
LQDA Liquidia	$89.16 +0.9%	$74.79	$19.02 ▼ $91.36	$7.91B	0.58	1.78 million shs	516,902 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	+1.60%	+0.85%	+7.26%	+0.68%	+125.35%
HRMY Harmony Biosciences	+8.93%	+8.41%	+4.08%	+18.30%	+9.12%
LNTH Lantheus	-0.08%	-1.49%	-7.99%	+17.37%	+41.49%
LQDA Liquidia	+5.40%	+1.80%	+11.97%	+109.73%	+353.70%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLTE Belite Bio	2.88	Moderate Buy	$203.00	29.11% Upside
HRMY Harmony Biosciences	2.50	Moderate Buy	$45.50	19.77% Upside
LNTH Lantheus	2.36	Hold	$108.11	6.55% Upside
LQDA Liquidia	2.82	Moderate Buy	$86.18	-3.33% Downside

Current Analyst Ratings Breakdown

Latest HRMY, LQDA, LNTH, and BLTE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2026	HRMY Harmony Biosciences	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold	$39.00
8/5/2026	HRMY Harmony Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$29.00 ➝ $34.00
8/5/2026	HRMY Harmony Biosciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$37.00
8/4/2026	HRMY Harmony Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$70.00
8/4/2026	LNTH Lantheus	CJS Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Market Outperform ➝ Market Perform
8/4/2026	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $50.00
8/3/2026	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$125.00 ➝ $102.50
8/3/2026	LNTH Lantheus	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$110.00 ➝ $102.50
8/3/2026	LNTH Lantheus	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$102.50
8/3/2026	LNTH Lantheus	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$102.50
8/3/2026	LNTH Lantheus	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform

(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLTE Belite Bio	N/A	N/A	N/A	N/A	$20.54 per share	N/A
HRMY Harmony Biosciences	$868.45M	2.53	$3.39 per share	11.19	$15.11 per share	2.51
LNTH Lantheus	$1.55B	4.27	$6.40 per share	15.85	$16.43 per share	6.18
LQDA Liquidia	$158.32M	50.08	N/A	N/A	$0.51 per share	174.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLTE Belite Bio	-$77.61M	-$2.53	N/A	N/A	N/A	N/A	-13.14%	-12.88%	8/10/2026 (Estimated)
HRMY Harmony Biosciences	$158.69M	$2.48	15.29	9.82	0.33	16.20%	17.19%	11.99%	N/A
LNTH Lantheus	$233.56M	$4.15	24.44	18.86	N/A	18.05%	29.32%	15.00%	8/6/2026 (Estimated)
LQDA Liquidia	-$68.92M	$0.14	635.76	16.79	N/A	7.74%	46.82%	7.06%	8/12/2026 (Estimated)

Latest HRMY, LQDA, LNTH, and BLTE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	LQDA Liquidia	$0.7580	N/A	N/A	N/A	$168.48 million	N/A
8/10/2026	Q2 2026	BLTE Belite Bio	-$0.73	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	LNTH Lantheus	$1.30	N/A	N/A	N/A	$363.19 million	N/A
8/4/2026	Q2 2026	HRMY Harmony Biosciences	$0.9560	$1.28	+$0.3240	$1.28	$250.77 million	$261.28 million
5/15/2026	Q1 2026	BLTE Belite Bio	-$0.60	-$0.34	+$0.26	-$0.68	N/A	N/A
5/11/2026	Q1 2026	LQDA Liquidia	$0.4102	$0.52	+$0.1098	$0.52	$119.44 million	$132.87 million
5/7/2026	Q1 2026	HRMY Harmony Biosciences	$0.76	$0.55	-$0.21	$0.55	$220.84 million	$215.39 million
5/7/2026	Q1 2026	LNTH Lantheus	$1.25	$1.46	+$0.21	$1.80	$354.48 million	$377.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLTE Belite Bio	N/A	33.71	33.71
HRMY Harmony Biosciences	0.15	3.58	3.56
LNTH Lantheus	0.47	2.83	2.64
LQDA Liquidia	1.18	2.22	2.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLTE Belite Bio	0.53%
HRMY Harmony Biosciences	86.23%
LNTH Lantheus	99.06%
LQDA Liquidia	64.54%

Insider Ownership

Company	Insider Ownership
BLTE Belite Bio	13.29%
HRMY Harmony Biosciences	11.00%
LNTH Lantheus	1.70%
LQDA Liquidia	25.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLTE Belite Bio	10	40.08 million	34.76 million	Not Optionable
HRMY Harmony Biosciences	200	57.89 million	51.53 million	Optionable
LNTH Lantheus	1,193	65.11 million	64.00 million	Optionable
LQDA Liquidia	50	88.93 million	66.16 million	Optionable

HRMY, LQDA, LNTH, and BLTE Headlines

Recent News About These Companies

3 Top Ranked Stocks Breaking Out Now

8 minutes ago | zacks.com

Liquidia (NASDAQ:LQDA) Reaches New 1-Year High - Here's Why

2 hours ago | marketbeat.com

Liquidia (LQDA) to Post Quarterly Earnings on Wednesday

August 5 at 7:40 AM | marketbeat.com

55,938 Shares in Liquidia Corporation $LQDA Purchased by Segall Bryant & Hamill LLC

August 5 at 5:11 AM | marketbeat.com

Sapient Capital LLC Cuts Stock Holdings in Liquidia Corporation $LQDA

August 4 at 5:35 AM | marketbeat.com

Empowered Funds LLC Acquires Shares of 96,717 Liquidia Corporation $LQDA

August 4 at 3:36 AM | marketbeat.com

Liquidia Corporation $LQDA is Seven Fleet Capital Management LP's 8th Largest Position

August 2 at 6:31 AM | marketbeat.com

DV Trading LLC Lowers Position in Liquidia Corporation $LQDA

August 2 at 4:23 AM | marketbeat.com

First Trust Advisors LP Sells 27,482 Shares of Liquidia Corporation $LQDA

August 1, 2026 | marketbeat.com

Should You Invest in Liquidia Corporation Stock Ahead of Q2 Earnings?

July 31, 2026 | zacks.com

Liquidia (NASDAQ:LQDA) Insider Sells 688 Shares

July 30, 2026 | insidertrades.com

Liquidia (NASDAQ:LQDA) Insider Sells $60,220.64 in Stock

July 29, 2026 | marketbeat.com

Insider Selling: Liquidia (NASDAQ:LQDA) CAO Sells 1,600 Shares of Stock

July 29, 2026 | marketbeat.com

Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026

July 29, 2026 | globenewswire.com

Liquidia (NASDAQ:LQDA) Director Sells $286,061.80 in Stock

July 29, 2026 | insidertrades.com

Liquidia (NASDAQ:LQDA) Director Sells 3,596 Shares of Stock

July 28, 2026 | marketbeat.com

Stephen Bloch Sells 75,000 Shares of Liquidia (NASDAQ:LQDA) Stock

July 28, 2026 | marketbeat.com

Insider Selling: Liquidia (NASDAQ:LQDA) Director Sells 100,000 Shares

July 28, 2026 | marketbeat.com

Liquidia Corporation (LQDA) Has 50%+ Upside on Yutrepia Ruling and Buyout Potential

July 28, 2026 | insidermonkey.com

Eversept Partners LP Purchases 167,949 Shares of Liquidia Corporation $LQDA

July 28, 2026 | marketbeat.com

LifeSci Capital Sticks to Their Buy Rating for Liquidia Technologies (LQDA)

July 27, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRMY, LQDA, LNTH, and BLTE Company Descriptions

Belite Bio NASDAQ:BLTE

$157.23 -0.04 (-0.03%)

As of 03:54 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Harmony Biosciences NASDAQ:HRMY

$37.99 -0.79 (-2.04%)

As of 03:54 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Lantheus NASDAQ:LNTH

$101.46 +0.36 (+0.35%)

As of 03:54 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Liquidia NASDAQ:LQDA

$89.16 +0.78 (+0.88%)

As of 03:54 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HRMY, LQDA, LNTH, and BLTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HRMY, LQDA, LNTH, and BLTE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HRMY, LQDA, LNTH, and BLTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRMY, LQDA, LNTH, and BLTE Company Descriptions

Belite Bio NASDAQ:BLTE

Harmony Biosciences NASDAQ:HRMY

Lantheus NASDAQ:LNTH

Liquidia NASDAQ:LQDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HRMY, LQDA, LNTH, and BLTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HRMY, LQDA, LNTH, and BLTE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HRMY, LQDA, LNTH, and BLTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRMY, LQDA, LNTH, and BLTE Company Descriptions

Belite Bio NASDAQ:BLTE

Harmony Biosciences NASDAQ:HRMY

Lantheus NASDAQ:LNTH

Liquidia NASDAQ:LQDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools